Navigation Links
Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood can potentially improve the quality of life for patients whose lower extremities are affected by peripheral vascular disease, according to a study in China.

SHENZHEN, China, July 02, 2007 /PRNewswire/ -- Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com) today announced that a team led by Dr. Yang Xiaofeng at its collaborating hospital in Shenyang completed a study to assess clinical efficacy, safety, and feasibility of transplantation of peripheral blood stem cells for patients with peripheral vascular disease of the lower extremities.

Beike is best known for its research and treatments for ataxia, cerebral palsy, spinal cord injury and MS which are often covered by China Stem Cell News (http://www.stemcellschina.com), a leading stem cell news site. However, Beike also has broad experience in research and treating vascular diseases with adult stem cells mostly through its collaboration with Shenyang 463 hospital.

A total of 152 patients with peripheral vascular disease of the lower extremities were enrolled into this non-controlled study from November 2003 to March 2006. The results were published in the Journal of Geriatric Cardiology which publishes original peer-reviewed clinical and experimental reports on all aspects of cardiovascular disease in the elderly.

A second study was completed during the same period comparing the relative improvement of lower limb ischemia (lack of blood supply) between transplantation of autologous peripheral blood stem cells and transplantation of bone marrow stem cells. The study is awaiting publication in a peer- reviewed journal.

At 12 weeks, primary symptoms, including lower limb pain and coldness, were significantly improved in 137 (90.1%) of the patients; limb ul
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Prana Biotechnology Presents New Key Findings on PBT2
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
6. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)... - Unprecedented amount of research reflects dep...rs worldwide to develop new treatments for ...y session to highlight impact of Zometa(R), the le...nts with early-stage breast cancer, - Four oral s...ontinuous, inhibitor of mTOR, including first resu...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 1Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2030 6Esperanza Announces Support of H R 1108 Encourages Congress to Pass FDA Regulation of Tobacco 18994 1Human aging gene found in flies 18989 1Human aging gene found in flies 18989 2Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs 3263 1Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs 3263 2
(Date:5/16/2008)...r Seeks to Raise $38 Million for Life-threatening,...wire/ -- Walkers in nearly,every state will raise ...nd,18 -- by participating in GREAT STRIDES, the la... Foundation announced today., May is National Cys...,life-threatening genetic disease that causes fata...
(Date:5/16/2008)...s is more unemployed politicians - and economists,... Although nearly all,voters place health care at t...oming federal budgetary crunch means none of the h...esidential candidates is likely to become,law anyt...Bill Frist., Jousting with Princeton University H...
(Date:5/16/2008)...PRNewswire-USNewswire/ -- As tropical storms,conti...elta, survivors of,Cyclone Nargis are vulnerable t...rs still need assistance, as exposure to the foul ...gly dire situation., "The people living in these ... this disaster and get back on their feet," said D...
(Date:5/16/2008)...., May 16 /PRNewswire-FirstCall/ -- Nationwide,Hea... the promotion of David,M. Boitano to Senior Vice ... made a tremendous contribution to NHP over the la...ment growth and diversification strategy,successes... accretive,investments for NHP, leveraging his vas...
Breaking Medicine News(10 mins):Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:David M. Boitano Promoted to Senior Vice President 2
...has issued a temporary regulation on human organ t... organ trade, under control // and regulate transp...s regarding organ transplantation and donation wou...y in the best interest of the patients. The new r...
... that lifted up faces and brought cheer to the Chu... tabs for three types of obesity surgery, in case...ms. // But the catch is that, only surgeries perf...ons or the American Society of Bariatric Surgery w...
...irst to chair some healthy practices in classrooms...stand for hours a day. // This follows a study, wh... to significant weight loss, as against sitting wh.... According to researchers, children were capable ...
... in the May 1, 2006 issue of CANCER, a peer-review...t weight training// improves the quality of life o... cancer. A bi-weekly exercise regimen for six mont...tional condition of the patients. In the initial ...
Other Medicine News:Health News:China Issues New Legislation To Ban Human Organ Trade 2Health News:Welcome to ‘Stand Only’ Classrooms That Exercise The Brain And The Bod 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 11 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm.
Medicine Products: